Core Viewpoint - HOOKIPA Pharma Inc. is in the process of a potential all-share acquisition of Poolbeg Pharma plc, with relevant U.K. disclosure requirements highlighted for shareholders [2][3][8]. Group 1: Acquisition Details - The acquisition was announced on January 2, 2025, and is subject to U.K. City Code on Takeovers and Mergers [2][3]. - Rule 8.3 of the Takeover Code mandates disclosures for shareholders holding 1% or more of relevant securities during the offer period [3]. - Relevant securities include HOOKIPA's common stock, Class A common stock, and various series of convertible preferred stock [3]. Group 2: Company Overview - HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutics for cancer and serious infectious diseases [5]. - The company utilizes a proprietary arenavirus platform to induce CD8+ T cells and antibodies targeting various cancers, including HPV16+ and KRAS mutated cancers [5]. - HOOKIPA has partnered with Gilead Sciences to develop therapies aimed at functional cures for hepatitis B and HIV-1 [5].

Potential Combination Update - Poolbeg Pharma and HOOKIPA Pharma are in discussions regarding a potential combination, with significant shareholder Gilead Sciences indicating its intention to vote in favor of the deal if a formal offer is made [2][3] - Gilead owns 1,875,947 HOOKIPA common shares, representing 19.4% of HOOKIPA's existing issued share capital [3] Fundraise Details - HOOKIPA has amended the details of its planned Fundraise, now expecting to undertake a 100% primary private placement fundraise of approximately $30 million+, up from the previously stated $30 million [4] - Oppenheimer & Co Inc has been engaged as the placement agent for the private placement fundraise [5] Advisors and Contacts - Poolbeg has engaged Cavendish Capital Markets, Canaccord Genuity, Shore Capital, and J&E Davy as financial advisers and brokers [6][7][14][15] - HOOKIPA has engaged Moelis & Company as its financial adviser [8][16] - Contact details for key executives and investor relations teams at both companies are provided [6][7]

Core Points - HOOKIPA Pharma Inc. has amended its previous announcement regarding the potential combination with Poolbeg Pharma plc, specifically correcting the ISIN of its common stock [2][3] - The correct ISIN for HOOKIPA's common stock is US43906K2096, effective after a 1-for-10 reverse stock split on July 9, 2024 [3][4] - HOOKIPA currently has 9,655,022 shares of common stock issued, along with additional classes of stock including Class A common stock and various series of convertible preferred stock [4][5] Stock Structure - HOOKIPA has 2,399,517 shares of Class A common stock, which can be converted into common stock at a ratio of 10:1, subject to ownership limitations [5][6] - The company also has 370 shares of Series A convertible preferred stock, 10,800 shares of Series A-1 convertible preferred stock, and 15,268 shares of Series A-2 convertible preferred stock, each convertible into 100 shares of common stock [5][6] - HOOKIPA has granted 369,070 shares of common stock in the form of restricted stock units as part of its incentive plans [7]

Financial Performance - The company reported a net loss of $13.8 million and $18.6 million for the three and nine months ended September 30, 2024, respectively, with an accumulated deficit of $387.8 million [151]. - The net loss for the three months ended September 30, 2024, was $13.8 million, an improvement of $5.2 million compared to a net loss of $19.1 million in the same period of 2023 [200]. - The net loss for the nine months ended September 30, 2024, was $18.6 million, compared to a net loss of $56.8 million for the same period in 2023 [229][230]. - The accumulated deficit as of September 30, 2024, was $387.8 million, with expectations of continued significant losses for the foreseeable future [218]. - The company does not expect positive cash flows from operations in the foreseeable future and anticipates incurring net operating losses for at least the next several years [214]. - Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the issuance date of the financial statements [216]. Revenue and Income - Revenue from collaboration and licensing was $4.7 million for the three months ended September 30, 2024, down from $6.9 million in the same period of 2023, representing a decrease of approximately 31.6% [182]. - For the nine months ended September 30, 2024, revenue increased to $42.6 million from $12.7 million in 2023, marking an increase of approximately 234.6% [182]. - The company recognized $36.4 million in revenue related to the terminated Roche Collaboration Agreement during the nine months ended September 30, 2024 [190]. - Other income for the three months ended September 30, 2024, was $1.8 million, compared to other expenses of $0.8 million for the same period in 2023, primarily due to exchange rate differences [205]. - For the nine months ended September 30, 2024, other income was $1.3 million, compared to other expenses of $1.0 million for the same period in 2023, also attributed to exchange rate differences [206]. Expenses - Research and development expenses for the three months ended September 30, 2024, totaled $15.6 million, compared to $24.6 million for the same period in 2023 [168]. - Total research and development expenses for the nine months ended September 30, 2024, were $55.5 million, compared to $65.3 million for the same period in 2023 [168]. - The company expects research and development expenses to increase substantially as it advances existing and future product candidates through clinical trials [165]. - General and administrative expenses increased to $6.7 million for the three months ended September 30, 2024, compared to $4.9 million in 2023, an increase of approximately 36.7% [195]. - Restructuring expenses for the three months ended September 30, 2024, were $0.9 million, with $0.8 million attributed to severance and other personnel costs [198]. - The company has established a full valuation allowance for deferred tax assets as of September 30, 2024, due to uncertainty in realizing benefits [180]. Cash and Funding - The company has cash, cash equivalents, and restricted cash of $60.0 million as of September 30, 2024 [147]. - Cash used in operating activities for the nine months ended September 30, 2024, was $56.0 million, an increase from $46.3 million in the same period of 2023 [229][230]. - Cash used in investing activities decreased to $0.2 million in the nine months ended September 30, 2024, from $3.7 million in the same period of 2023 [231][232]. - Cash used in financing activities was $1.3 million for the nine months ended September 30, 2024, compared to cash provided of $44.4 million in the same period of 2023 [233][234]. - The company anticipates requiring additional funding to support clinical and preclinical development, regulatory approvals, and operational expansions [219]. - The company has no committed external source of funds for its development efforts and expects to finance future cash needs through a combination of equity offerings, debt financings, and collaborations [225]. Research and Development - The eseba-vec program for HPV16+ head and neck cancers showed an overall response rate (ORR) of 55.0% in the selected Phase 3 dose group, with a disease control rate (DCR) of 75% [137]. - The combination treatment of eseba-vec with pembrolizumab demonstrated a favorable safety profile, with serious adverse events in only 7.6% of participants [139]. - The company received FDA clearance for HB-700 in April 2024, targeting KRAS mutated cancers, including lung, colorectal, and pancreatic cancers [140]. - The collaboration with Gilead for the HBV program has the potential for up to $185.0 million in milestone payments, plus tiered royalties [142]. - The company regained full control of the HB-700 program after Roche terminated their collaboration agreement, receiving a non-refundable upfront payment of $25.0 million and milestone payments of $20.0 million [141]. - The company regained full control of the intellectual property portfolio associated with the terminated Roche Collaboration Agreement effective April 25, 2024 [158]. - The company recognized $0.6 million in cost reimbursements for research and development activities related to a first human trial [160]. Market Risks - The company is subject to market risks from changes in interest rates, foreign exchange rates, and inflation, which may impact financial performance [241][243]. - The company anticipates that a significant portion of its expenses will continue to be denominated in euros, exposing it to foreign currency risk [241].

Clinical Trials - Enrollment of 68 patients completed in Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC, four months ahead of schedule[1] - First patients dosed in Phase 2 investigator-initiated study for eseba-vec in adjuvant therapy for head and neck cancer[3] - The HB-700 program is ready for Phase 1 trials, targeting KRAS-mutated cancers, with FDA clearance received in April 2024[5] - HOOKIPA received a $5 million milestone payment from Gilead in July 2024 related to the HB-500 clinical trial[12] Financial Performance - Revenue for Q3 2024 was $4.7 million, a decrease of 31.6% from $6.9 million in Q3 2023, primarily due to lower partnering revenues[14] - Net loss for Q3 2024 was $13.8 million, compared to a net loss of $19.1 million in Q3 2023, representing a 27.3% improvement[18] Expenses - Research and development expenses decreased to $15.6 million in Q3 2024 from $24.6 million in Q3 2023, reflecting lower personnel and laboratory-related expenses[15] - General and administrative expenses increased to $6.7 million in Q3 2024 from $4.9 million in Q3 2023, driven by higher personnel-related expenses and consulting fees[16] Cash Position - Cash position as of September 30, 2024, was $60.0 million, down from $117.5 million as of December 31, 2023, primarily due to cash used in operating activities[13] - As of September 30, 2024, cash, cash equivalents, and restricted cash totaled $59,957,000, down from $117,521,000 as of December 31, 2023[24] Assets and Liabilities - Total assets decreased to $109,730,000 from $161,337,000[24] - Total liabilities reduced to $37,928,000 compared to $71,480,000[24] - Total stockholders' equity declined to $71,802,000 from $89,857,000[24] Corporate Actions - A reverse stock split of 1-for-10 was executed on July 9, 2024, to comply with Nasdaq listing requirements[11]

Core Insights - HOOKIPA Pharma Inc. is presenting preclinical data for its HB-700 program targeting KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit in Boston from September 24-26, 2024 [1][2] Company Overview - HOOKIPA is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapeutics using its proprietary arenavirus platform [3] - The company aims to induce specific, robust, and durable CD8+ T cells and antibodies to combat cancers and serious infectious diseases [3] - HOOKIPA's pipeline includes therapies for HPV16+ cancers, KRAS mutated cancers, and partnerships with Gilead for hepatitis B and HIV-1 treatments [3] Product Development - The HB-700 program is designed to target the most prevalent KRAS mutations found in pancreatic, colorectal, and lung cancers [2] - The preclinical dataset for HB-700 has shown safety, induction of target-specific CD8+ T-cells, and effective target cell killing in various animal and translational models [2] - The program has received IND clearance from the FDA in Q2 2024, making it ready for Phase 1 trials [2]

Core Viewpoint - HOOKIPA Pharma Inc. has announced leadership changes in its Board of Directors, with Julie O'Neill appointed as Non-Executive Chair, succeeding Jan van de Winkel, who stepped down due to increased commitments as CEO of Genmab A/S, and Tim Reilly also stepping down to focus on other responsibilities [1][2]. Company Overview - HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies based on its proprietary arenavirus platform, aimed at mobilizing and amplifying targeted T cells to combat serious diseases [3]. - The company's pipeline includes investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs, as well as efforts to develop functional cures for HBV and HIV in collaboration with Gilead [3].

Core Insights - HOOKIPA Pharma Inc. has made significant progress in its clinical development pipeline, particularly with its lead product candidate eseba-vec, which is on track for a pivotal Phase 2/3 trial initiation in Q4 2024 [1][3][4] - The company has received positive regulatory feedback, including alignment with the FDA for the AVALON-1 trial design and PRIME designation from the EMA for eseba-vec [1][3] - HOOKIPA has also expanded its oncology portfolio with the FDA clearance of its IND application for HB-700, targeting KRAS-mutated cancers [5] Leadership and Corporate Updates - Malte Peters has been appointed as the new CEO, emphasizing optimism about the company's prospects and the strength of its pipeline [2] - The company executed a reverse stock split on a one-for-ten basis to comply with Nasdaq listing requirements [7] Clinical Development Highlights - The Phase 2 data for eseba-vec presented at ASCO 2024 has generated significant momentum, enhancing enrollment in ongoing studies [2][4] - The AVALON-1 trial for eseba-vec is expected to start in Q4 2024, with a focus on HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma [3][4] Financial Performance - HOOKIPA reported a revenue of $1.3 million for Q2 2024, down from $2.7 million in Q2 2023, primarily due to the termination of the Roche collaboration [10] - The company's net loss for Q2 2024 was $19.1 million, slightly higher than the $18.0 million loss in the same period of 2023 [14] - As of June 30, 2024, HOOKIPA's cash position was $77.4 million, a decrease from $117.5 million at the end of 2023 [9][16] Research and Development Updates - HOOKIPA is actively enrolling patients in the Phase 1b trial for HB-500, an investigational therapeutic vaccine for HIV, in collaboration with Gilead [6] - The company is also evaluating partnerships for the HB-700 program targeting KRAS-mutated cancers [3][5]

Core Viewpoint - HOOKIPA Pharma Inc. (HOOK) has seen a 0.6% increase in share price over the past four weeks, closing at $5.12, with Wall Street analysts suggesting a potential upside of 634.4% based on a mean price target of $37.60 [1] Price Targets - The average price target consists of five estimates ranging from a low of $15 to a high of $60, with a standard deviation of $18.61, indicating variability among analysts [2] - The lowest estimate suggests a 193% increase from the current price, while the highest indicates a 1071.9% upside [2] Analyst Consensus and Earnings Estimates - Analysts are increasingly optimistic about HOOK's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 25.7%, with one estimate increasing and no negative revisions [10] Zacks Rank - HOOK currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11]

Core Insights - HOOKIPA Pharma Inc. has appointed Dr. Malte Peters as CEO and Terry Coelho as CFO, effective July 22, 2024, both retaining their positions on the Board of Directors [1][9][22] - The company is entering a critical phase for its lead candidate HB-200, having received PRIME designation from the European Medicines Agency and aligning on a clinical development strategy with the U.S. FDA for potential accelerated approval [2][30] - The company is also advancing its other programs, including HB-500 for HIV treatment, with the first patient recently dosed in a Phase 1b clinical trial [2][30] Leadership Changes - Dr. Malte Peters has extensive experience in the pharmaceutical and biotech industries, previously serving as Chief Research and Development Officer at MorphoSys [4][11] - Terry Coelho has over 35 years of experience in finance and business development, having held various executive roles, including CFO at Gamida Cell and CinCor Pharma [6][13] - Sean Cassidy has been appointed to the Board of Directors, bringing over 20 years of experience in the biotechnology and pharmaceutical sectors [10][28] Product Development - HB-200 is HOOKIPA's lead oncology candidate, engineered with a proprietary replicating arenaviral vector platform, targeting HPV16-positive cancers [8][30] - The company is conducting a review of its business operations and strategy to maximize shareholder value and the potential of HB-200 [9][23] - HOOKIPA's pipeline includes investigational immunotherapies targeting various cancers and aims to develop functional cures for HBV and HIV in collaboration with Gilead [18][30]